Delcath Systems, Inc. (NASDAQ:DCTH) Sees Significant Growth in Short Interest

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 986,900 shares, an increase of 5.3% from the January 15th total of 937,100 shares. Based on an average daily volume of 437,700 shares, the short-interest ratio is presently 2.3 days.

Institutional Trading of Delcath Systems

Several institutional investors and hedge funds have recently modified their holdings of DCTH. Soleus Capital Management L.P. bought a new stake in shares of Delcath Systems during the fourth quarter valued at approximately $9,644,000. Vivo Capital LLC increased its holdings in Delcath Systems by 71.4% during the fourth quarter. Vivo Capital LLC now owns 1,708,579 shares of the company's stock valued at $20,571,000 after buying an additional 711,574 shares during the period. Gilder Gagnon Howe & Co. LLC purchased a new position in Delcath Systems during the fourth quarter valued at approximately $7,371,000. Polar Asset Management Partners Inc. purchased a new position in Delcath Systems during the third quarter valued at approximately $1,594,000. Finally, Jane Street Group LLC increased its holdings in Delcath Systems by 1,364.6% during the fourth quarter. Jane Street Group LLC now owns 178,797 shares of the company's stock valued at $2,153,000 after buying an additional 166,589 shares during the period. Institutional investors own 61.12% of the company's stock.

Delcath Systems Trading Down 4.2 %

Shares of Delcath Systems stock traded down $0.66 on Friday, hitting $14.88. 240,895 shares of the company traded hands, compared to its average volume of 429,335. The stock's 50 day moving average price is $13.97 and its 200-day moving average price is $11.24. Delcath Systems has a 52 week low of $3.70 and a 52 week high of $16.97. The company has a market cap of $475.77 million, a PE ratio of -11.02 and a beta of 0.86.

Wall Street Analysts Forecast Growth

DCTH has been the subject of several analyst reports. Craig Hallum raised their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of Delcath Systems in a research note on Tuesday, January 14th. Finally, StockNews.com raised shares of Delcath Systems from a "sell" rating to a "hold" rating in a research note on Friday, October 25th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $22.25.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.